Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies

被引:156
作者
Del Prato, S. [1 ]
机构
[1] Univ Pisa, Dept Endocrinol & Metab, Sect Metab Dis & Diabet, Pisa, Italy
关键词
B-cell function; B-cell mass; glucotoxicity; insulin secretion; lipotoxicity; FREE FATTY-ACIDS; BETA-CELL APOPTOSIS; GLUCOSE COTRANSPORTER SGLT2; INSULIN-RESISTANCE; PANCREATIC-ISLETS; GLYCEMIC CONTROL; RISK-FACTORS; IN-VITRO; INHIBITOR; SECRETION;
D O I
10.1111/j.1464-5491.2009.02847.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes mellitus is a disease characterized by persistent and progressive deterioration of glucose tolerance. Both insulin resistance and impaired insulin secretion contribute to development of Type 2 diabetes. However, whilst insulin resistance is fully apparent in the pre-diabetic condition, impairment of insulin secretion worsens over the time, being paralleled by a progressive decline in both pancreatic B-cell function and B-cell mass. Intense research has identified a number of genetic variants that may predispose to impaired B-cell function, but such predisposition can be precipitated and worsened by toxic effects of hyperglycaemia (glucotoxicity) and elevated levels of free fatty acids (lipotoxicity). All these aspects of the pathogenesis of Type 2 diabetes are discussed in this review. Moreover, treatments that target reduction in glucotoxicity or lipotoxicity are outlined, including emerging strategies that target the role of glucagon-like peptide 1 and sodium glucose co-transporter 2.
引用
收藏
页码:1185 / 1192
页数:8
相关论文
共 53 条
[21]   Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats [J].
Han, Songping ;
Hagan, Deborah L. ;
Taylor, Joseph R. ;
Xin, Li ;
Meng, Wei ;
Biller, Scott A. ;
Wetterau, John R. ;
Washburn, William N. ;
Whaley, Jean M. .
DIABETES, 2008, 57 (06) :1723-1729
[22]   The incretin system and its role in type 2 diabetes mellitus [J].
Holst, Jens Juul ;
Vilsboll, Tina ;
Deacon, Carolyn F. .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2009, 297 (1-2) :127-136
[23]  
Hussey EK, 2007, DIABETES, V56, pA49
[24]   A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes [J].
Kashyap, S ;
Belfort, R ;
Gastaldelli, A ;
Pratipanawatr, T ;
Berria, R ;
Pratipanawatr, W ;
Bajaj, M ;
Mandarino, L ;
DeFronzo, R ;
Cusi, K .
DIABETES, 2003, 52 (10) :2461-2474
[25]   Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level [J].
Katsuno, Kenji ;
Fujimori, Yoshikazu ;
Takemura, Yukiko ;
Hiratochi, Masahiro ;
Itoh, Fumiaki ;
Komatsu, Yoshimitsu ;
Fujikura, Hideki ;
Isaji, Masayuki .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 320 (01) :323-330
[26]  
Komoroski B, 2009, CLIN PHARMACOL THER, V85, P558
[27]   Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects [J].
Komoroski, B. ;
Vachharajani, N. ;
Boulton, D. ;
Kornhauser, D. ;
Geraldes, M. ;
Li, L. ;
Pfister, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (05) :520-526
[28]   Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus [J].
Komoroski, B. ;
Vachharajani, N. ;
Feng, Y. ;
Li, L. ;
Kornhauser, D. ;
Pfister, M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (05) :513-519
[29]   THE CONTRIBUTION OF HYPERGLYCEMIA AND HYPOINSULINEMIA TO THE INSULIN RESISTANCE OF STREPTOZOTOCIN-DIABETIC RATS [J].
LISATO, G ;
CUSIN, I ;
TIENGO, A ;
DELPRATO, S ;
JEANRENAUD, B .
DIABETOLOGIA, 1992, 35 (04) :310-315
[30]   Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes [J].
List, James F. ;
Woo, Vincent ;
Morales, Enrique ;
Tang, Weihua ;
Fiedorek, Fred T. .
DIABETES CARE, 2009, 32 (04) :650-657